A failed trial at the American Heart Association leads to pointed fingers at game-changing research on Vascepa, and counter claims of "manufactured controversy."
July 02, 2022
In COVID-19 news, the FDA has declined an EUA request for Zyesami and Pfizer has submitted NDA for Pavlovid. The regulatory agency has accepted several applications, including an sBLA for Eylea in diabetic retinopathy and the NDA for palovarotene for a rare genetic disorder. The FDA also issued a CRL for a UTI therapy and extended the review of diabetes therapy. And finally, Gilead has resubmitted its twice-year HIV therapy.
July 01, 2022
By using a combination of predictive and prescriptive next best action insights, providers can close the gap in care for individual patients by leveraging a combination of data sources — clinical data, patient surveys, SDOH data, and consumer and behavioral data sets — and applying artificial intelligence techniques to create those insights.
July 01, 2022
The companies issued statements referencing out-of-state abortions and travel benefits. Both are in headquartered in states with strong abortion rights laws.
June 30, 2022
Improving interfacility patient movement is an art and a science: to be well-executed, it requires clinical judgment and aggregated data.
June 30, 2022
The Association for Community Affiliated Plans has launched The ACAP Center for Social Determinants of Health Innovation. The center offers tailored resources, including policy reports, market research, and roundtable educational events, to help health plans, policymakers, and other stakeholders address social issues that impact health and wellbeing
June 30, 2022
Epic research suggests that like COVID-19, flu and other viral pneumonias can result in long-term symptoms like fatigue and brain fog. Why that might be is an open question.
June 29, 2022
A recent issue brief from the Kaiser Family Foundation says anxiety and depression, drug overdose deaths, self-harm and eating disorders have increased in adolescents as access and utilization of mental health care has declined.
June 25, 2022
FDA approves tumor-agnostic cancer therapy, Clovis pulls Rubraca indication, Purdue launches opioid reversal, FDA plans advisory committee meeting for Xphozah, and Manarini and AbbVie submit applications.
June 24, 2022
Certain problems such as pain/discomfort, worrying and fear of the persistence/recurrence of atopic dermatitis (AD) became more common among patients with AD since the start of the COVID-19 pandemic.
June 23, 2022
Respondents can win a $250 gift card.